PaedNeoVax Clinical Trial Opens to Target Aggressive Childhood Brain Tumours

Brain cancer remains one of the most complex and devastating diagnoses in paediatric medicine. Finding effective treatments for relapsed or treatment-resistant high-grade tumours requires innovative thinking and national collaboration.

A vital milestone has just been reached for the Australian research community. The world-first PaedNeoVax clinical trial has officially opened, aiming to assess the safety and feasibility of personalised mRNA cancer vaccines for children and adolescents.

The Science of Personalised Vaccines

Every child’s cancer is unique, which means standard treatments do not always work for everyone. PaedNeoVax uses advanced genome sequencing to identify specific targets within an individual child’s tumour. By creating a bespoke mRNA vaccine for each participant, the therapy is designed to train the child’s immune system to recognise and attack the cancer cells.

This approach offers potential new avenues for treating conditions such as medulloblastoma, ependymoma, high-grade glioma, and diffuse midline glioma.

Current Trial Sites and Enrolment Update

As the trial’s Regulatory Sponsor, ANZCHOG is pleased to confirm that PaedNeoVax is now active. The trial is open at Sydney Children’s Hospital, Perth Children’s Hospital, and the Women’s and Children’s Hospital, Adelaide, and the four available screening places have been allocated

We understand that families facing a brain cancer diagnosis are urgently seeking new options. Clinical trials of this nature must proceed with the utmost caution to ensure patient safety and the integrity of the medical data. The research team will be closely monitoring these initial participants and as National Principal Investigator for PaedNeoVax Professor Jordan Hansford says below, are very hopeful.

"Our team is excited to offer this world-first therapy for high-risk brain tumours. Most of these kids have few options, and we are very hopeful this new and exciting treatment option will help them."

A Collaborative Effort

Delivering a study of this scale is only possible through deep collaboration. With our partners at QIMR Berghofer and Providence Therapeutics, the trial is supported by funding from the Australian Government’s Medical Research Futures Fund (MRFF), The Robert Connor Dawes Foundation, The Marcus Rosin Fund and The Children’s Cancer Foundation.

For families seeking more information about clinical trial participation, please speak with your primary treating oncologist or visit our clinical trials registry via the link below.

Interested in other trials?

Visit our comprehensive clinical trials repository.

Share the Post:

Related Posts